Document:

<PAGE>   1
                                                                   EXHIBIT 10.22

                                 PROMISSORY NOTE

PRINCIPAL $500,000.                                    DATE: SEPTEMBER 22, 2000.

     1. PRINCIPAL AND INTEREST. Ampersand Medical Corporation, a corporation
organized and existing under the laws of the State of Delaware (the "Company"),
with offices at 414 N. Orleans St., Suite 510, Chicago, Illinois, 60610 for
value received, hereby promises to pay to the order of Azimuth Corporation (the
"Holder"), with offices at 3600 Rio Vista Avenue, Suite A, Orlando, Florida
32805, or any successor in interest in lawful money of the United States at the
address of the Holder set forth below, the principal sum of Five Hundred
Thousand and 00/100 Dollars ($500,000) one year from the date hereof (the
"Maturity Date"), together with simple interest from the date hereof, computed
on the basis of a 365-day year from the date of original issuance until the
Maturity Date, or such earlier payment date as described below, at the rate of
15% per annum.

     2. PREPAYMENT. The principal amount of the Note, plus any accrued interest
due thereon, may be prepaid in its entirety at any time after the expiration of
a period of 180 days from the original issue date of the Note. The Company shall
provide written notification to the Holder of its intention to prepay the Note.
Such written notification shall be made to the Holder not less than 15 business
days prior to the intended prepayment date.

     3. CONVERSION. If the Company provides written notification to the Holder
of its intention to prepay the Note and accrued interest due thereon in
accordance with the terms of the Section 2., above, the Holder may, at his/her
option, upon notice to the Company elect to convert the Note plus accrued
interest due thereon into shares of Common Stock of the Company at a Conversion
Rate described in Section 4., below. In the absence of a prepayment
notification, the Holder may, after the expiration of a period of 180 days from
the original issue date of the Note, at his/her option, upon notice to the
Company elect to convert the Note plus accrued interest due thereon into shares
of Common Stock of the Company.

     4. CONVERSION RATE. Subject to compliance with Section 3., above, the
principal of the Note plus accrued interest due thereon, shall be convertible
into shares of Common Stock of the Company at the Conversion Rate (the
"Conversion Rate") of One Dollar ($1.00) per share, subject to adjustment as
described in Section 5., below.

     5. RECLASSIFICATION, ETC. If the Company at any time shall, by subdivision,
combination or reclassification of securities or otherwise, change any of the
securities into which the Note is convertible into the same or a different
number of securities of any class or classes of securities of the Company, or
exchange any such securities in a merger or acquisition for securities or
property of another Company, the Holder shall be entitled to the same rights in
such new securities or property as the Holder would have been entitled to if
immediately prior to such change the Holder had acquired shares of Common Stock
into which the Note is convertible.

<PAGE>   2

     6. USE OF PROCEEDS. The proceeds of the Note shall be use to (i) make
License payments under a certain Technology and Development License between the
Company and Invirion, Inc.; (ii) fund payments required under a settlement
agreement between the Company and its former legal counsel; and, (iii) fund the
payment of an earnest money deposit under an agreement between the Company and
AccuMed International, Inc relating to the merger of the two companies, and for
no other purpose.

     7. GOVERNING LAW. The Note is delivered in and shall be construed in
accordance with the laws of the State of Illinois, without regard to conflicts
of laws provisions thereof.

        IN WITNESS WHEREOF, and intending to be legally bound hereby, the
Company has caused this Note to be executed and delivered by its proper and duly
authorized officers as of the date first above written.

AMPERSAND MEDICAL CORPORATION

BY:________________________________

NAME:  LEONARD R. PRANGE
TITLE: PRESIDENT, COO/CFO<PAGE>   1
                                                                   EXHIBIT 10.23
                                 PROMISSORY NOTE

PRINCIPAL $500,000.                                       DATE: NOVEMBER 1, 2000

     1. PRINCIPAL AND INTEREST. Ampersand Medical Corporation, a corporation
organized and existing under the laws of the State of Delaware (the "Company"),
with offices at 414 N. Orleans St., Suite 510, Chicago, Illinois, 60610 for
value received, hereby promises to pay to the order of MONSUN A/S (By Mr. Magne
Jordanger) (the "Holder"), with offices at Torvveien 12, 1372 Asker, Norway, or
any successor in interest in lawful money of the United States at the address of
the Holder set forth below, the principal sum of Five Hundred Thousand and
00/100 Dollars ($500,000) one year from the date hereof (the "Maturity Date"),
together with simple interest from the date hereof, computed on the basis of a
365-day year from the date of original issuance until the Maturity Date, or such
earlier payment date as described below, at the rate of 15% per annum.

     2. PREPAYMENT. The principal amount of the Note, plus any accrued interest
due thereon, may be prepaid in its entirety at any time after the expiration of
a period of 180 days from the original issue date of the Note. The Company shall
provide written notification to the Holder of its intention to prepay the Note.
Such written notification shall be made to the Holder not less than 15 business
days prior to the intended prepayment date.

     3. CONVERSION. If the Company provides written notification to the Holder
of its intention to prepay the Note and accrued interest due thereon in
accordance with the terms of the Section 2., above, the Holder may, at his/her
option, upon notice to the Company elect to convert the Note plus accrued
interest due thereon into shares of Common Stock of the Company at a Conversion
Rate described in Section 4., below. In the absence of a prepayment
notification, the Holder may, after the expiration of a period of 180 days from
the original issue date of the Note, at his/her option, upon notice to the
Company elect to convert the Note plus accrued interest due thereon into shares
of Common Stock of the Company.

     4. CONVERSION RATE. Subject to compliance with Section 3., above, the
principal of the Note plus accrued interest due thereon, shall be convertible
into shares of Common Stock of the Company at the Conversion Rate (the
"Conversion Rate") of One Dollar ($1.00) per share, subject to adjustment as
described in Section 5., below.

     5. RECLASSIFICATION, ETC. If the Company at any time shall, by subdivision,
combination or reclassification of securities or otherwise, change any of the
securities into which the Note is convertible into the same or a different
number of securities of any class or classes of securities of the Company, or
exchange any such securities in a merger or acquisition for securities or
property of another Company, the Holder shall be entitled to the same rights in
such new securities or property as the Holder would have been entitled to if
immediately prior to such change the Holder had acquired shares of Common Stock
into which the Note is convertible.

<PAGE>   2

     6. USE OF PROCEEDS. The proceeds of the Note shall be used to (i) make
License payments under a certain Technology and Development License between the
Company and Invirion, Inc.; (ii) fund payments required under a settlement
agreement between the Company and its former legal counsel; and, (iii) fund the
payment of development costs for instruments and other component devices, and
for no other purpose.

     7. GOVERNING LAW. The Note is delivered in and shall be construed in
accordance with the laws of the State of Illinois, without regard to conflicts
of laws provisions thereof.

        IN WITNESS WHEREOF, and intending to be legally bound hereby, the
Company has caused this Note to be executed and delivered by its proper and duly
authorized officers as of the date first above written.

AMPERSAND MEDICAL CORPORATION

BY:________________________________

NAME:  LEONARD R. PRANGE
TITLE: PRESIDENT, COO/CFO<PAGE>   1
                                                                   EXHIBIT 10.24

                                 PROMISSORY NOTE

PRINCIPAL $200,000.                                       DATE: DECEMBER 4, 2000

     1. PRINCIPAL AND INTEREST. Ampersand Medical Corporation, a corporation
organized and existing under the laws of the State of Delaware (the "Company"),
with offices at 414 N. Orleans St., Suite 510, Chicago, Illinois, 60610 for
value received, hereby promises to pay to the order of Azimuth Corporation (the
"Holder"), with offices at 3600 Rio Vista Avenue, Suite A, Orlando, Florida
32805, or any successor in interest in lawful money of the United States at the
address of the Holder set forth below, the principal sum of Two Hundred Thousand
and 00/100 Dollars ($200,000) on December 31, 2000 (the "Maturity Date"),
together with simple interest from the date hereof, computed on the basis of a
365-day year from the date of original issuance until the Maturity Date, or such
earlier payment date as described below, at the rate of 12% per annum.

     2. PREPAYMENT. The principal amount of the Note, plus any accrued interest
due thereon, may be prepaid in its entirety at any time.

     3. ADDITIONAL CONSIDERATION. The Company will issue a warrant (attached as
an exhibit) entitling the Holder to purchase 50,000 shares of Common Stock of
the Company at an exercise price of $0.937 per share, representing the closing
price of the Company's Common Stock as listed on the OTC:BB on November 30,
2000.

     4. DEFAULT PENALTY PROVISIONS. If the Company fails to pay the principal
and accrued interest due thereon on the maturity date, interest shall continue
to accrue as computed above at an adjusted rate of 15% per annum from the
Maturity Date until the date the note and accrued interest is paid in full. In
addition, for each month, up to a maximum of three months, beyond the maturity
date that the principal remains unpaid, the Company shall issue a warrant
entitling the Holder to purchase 12,500 shares of Common Stock at an exercise
price of $0.01 per share. If the principal remains unpaid after the expiration
of a three-month period from the Maturity Date, for each subsequent month the
principal remains outstanding, the Company shall issue a warrant entitling the
Holder to purchase 25,000 shares of Common Stock at an exercise price of $0.01
per share.

     5. RECLASSIFICATION, ETC. If the Company at any time shall, by subdivision,
combination or reclassification of securities or otherwise, change any of the
securities into which the attached warrant is convertible into the same or a
different number of securities of any class or classes of securities of the
Company, or exchange any such securities in a merger or acquisition for
securities or property of another Company, the Holder shall be entitled to the
same rights in such new securities or property as the Holder would have been
entitled to if immediately prior to such change the Holder had acquired shares
of Common Stock into which the warrant is convertible.

<PAGE>   2

     6. USE OF PROCEEDS. The proceeds of the Note shall be used to (i) fund the
quarterly payment due December 1, 2000 under a contract dated December 1, 2000
with University Hospitals of Cleveland; and (ii) the remainder for general
corporate purposes.

     7. GOVERNING LAW. The Note is delivered in and shall be construed in
accordance with the laws of the State of Illinois, without regard to conflicts
of laws provisions thereof.

        IN WITNESS WHEREOF, and intending to be legally bound hereby, the
Company has caused this Note to be executed and delivered by its proper and duly
authorized officers as of the date first above written.

AMPERSAND MEDICAL CORPORATION

BY:________________________________

NAME:  LEONARD R. PRANGE
TITLE: PRESIDENT, COO/CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}]]